Ex-'King of Biotech' set to serve four-year term for fraud

NEW YORK Tue Jan 21, 2014 11:39pm IST

Related Topics

Stocks

   

NEW YORK (Reuters) - David Blech, once dubbed the "King of Biotech", failed to persuade a U.S. appeals court to throw out his four-year prison term for securities fraud on the ground that his sentencing judge was biased.

Blech, 58, had argued in court papers that U.S. District Judge Colleen McMahon improperly considered his race and social status in imposing the sentence.

The defendant, who is white, Jewish and was once among the wealthiest Americans, said McMahon wanted to counter a view that "we let people like you get away with things that we don't let poor black drug addicts" get away with.

In an order on Tuesday, the 2nd U.S. Circuit Court of Appeals said McMahon "made a number of ill‐conceived remarks that bordered on the inappropriate," but that it was not persuaded that she sentenced Blech "based on unconstitutional factors such as race".

It said McMahon sentenced Blech based on factors including "the need for specific deterrence for a recidivist, and the need for general deterrence for those who might otherwise feel that some white‐collar crimes are 'games worth playing.'"

The court also upheld McMahon's $1.34 million forfeiture order, saying Blech waited too long to object.

Richard Levitt, a lawyer for Blech, declined to comment. The defendant had sought to be resentenced by a different judge.

Blech, who has said he has bipolar disorder, had pleaded guilty in May 2012 to manipulating shares of biopharmaceutical companies Pluristem Therapeutics Inc (PSTI.O) and Intellect Neurosciences Inc ILNS.PK in 2007 and 2008.

He reached a $1.03 million civil settlement last August with the U.S. Securities and Exchange Commission.

Blech had also pleaded guilty in 1998 to an unrelated fraud, but was sentenced to probation.

Earlier in his career, Blech helped found Celgene Corp (CELG.O), whose products include the blood cancer drug Revlimid, and whose market value on Friday topped $68 billion.

He also helped found Icos Corp, now part of Eli Lilly & Co (LLY.N), which developed Cialis to treat erectile dysfunction.

Forbes magazine said Blech was worth $295 million in 1992, making him among the 400 richest Americans.

Blech is housed at a low-security prison in Fort Dix, New Jersey. He is not eligible for release until March 12, 2017.

The case is U.S. v. Blech, 2nd U.S. Circuit Court of Appeals, No. 13-1881.

(Reporting by Jonathan Stempel; Editing by Stephen Powell)

FILED UNDER:

"India's Daughter"

Reuters Showcase

Microfinance

Microfinance

Funding the unfunded: India helps small business borrow to grow  Full Article 

Insurance Sector

Insurance Sector

UK healthcare firm Bupa sees strong growth in India  Full Article 

Sensex Rises

Sensex Rises

Sensex edges up; consumer and healthcare stocks rise  Full Article 

Market Eye

Market Eye

FTSE adds nine Indian firms as large-caps in Asia-Pacific ex-Japan index   Full Article 

Indian Ocean Diplomacy

Indian Ocean Diplomacy

PM Modi to ramp up help for Indian Ocean nations to counter China influence  Full Article 

ECB Bond-Buying

ECB Bond-Buying

ECB raises growth forecasts, to start printing money next week  Full Article 

China Economy

China Economy

China signals "new normal" with lower annual growth target  Full Article 

Pharma Sector

Pharma Sector

Panel recommends waiving late-stage trials for some drugs  Full Article 

E-commerce

E-commerce

China backs e-commerce expansion in win for Alibaba, JD.com  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage